A recent judgment from the California Supreme Court has critical repercussions for pharmaceutical and medical device manufacturers facing failure-to-warn claims in the state. The decision clarifies the evidence required to prove causation in such cases, following a query by the US Court of Appeals for the Ninth Circuit. The court determined that plaintiffs must show that a stronger warning would have not only altered the physician’s prescribing decision but also that a reasonable patient would have declined treatment based on the stronger warning, as elucidated in Himes v. Somatics.
The court adopted the “reasonably prudent person” standard from medical malpractice informed consent jurisprudence, suggesting that the assessment might include specific patient characteristics or circumstances. Jurors could consider patients’ medical histories, emotional states, risk tolerance, the novelty of the treatment, available alternatives, severity of the condition, and the potential benefit when deciding if a reasonably prudent person would have refused treatment given new or additional warnings.
This approach marks a shift from traditional pharmaceutical and medical device failure-to-warn cases, urging manufacturers to reevaluate their strategies. They must now delve deeper into individual patient factors during discovery, engage with experts, and integrate these aspects into trial proceedings.
The ruling also reaffirms the learned intermediary doctrine within an evolving doctor-patient dynamic, shaped by technological advancements that empower patients with medical information. While appreciating greater patient autonomy in medical decisions, the court emphasized that the duty to warn still primarily resides with the physician. Therefore, the physician’s testimony remains pivotal in the causation analysis.
The judgment highlighted that for a failure-to-warn claim to succeed, proof must begin with the physician’s role in communicating risks. Even if a physician indicated they would have provided new risk information, plaintiffs must still demonstrate that an “objectively prudent person” would have refused the treatment based on this new information.
These clarified evidentiary standards ensure that the learned intermediary doctrine continues to be a significant counterbalance in defending against liability claims in California. For further details, readers can access the full case documentation through Bloomberg Law.
This information foregrounds the need for legal professionals representing medical manufacturers to review and possibly adapt their litigation approaches in light of this precedent.